AAAAAA

   
Results: 1-3 |
Results: 3
Expression and activation of a C-terminal truncated isoform of STAT5 (STAT5 Delta) following interleukin 2 administration or AZT monotherapy in HIV-infected individuals
Authors: Bovolenta, C Camorali, L Mauri, M Ghezzi, S Nozza, S Tambussi, G Lazzarin, A Poli, G
Citation: C. Bovolenta et al., Expression and activation of a C-terminal truncated isoform of STAT5 (STAT5 Delta) following interleukin 2 administration or AZT monotherapy in HIV-infected individuals, CLIN IMMUNO, 99(1), 2001, pp. 75-81
Efficacy of low-dose intermittent subcutaneous interleukin (IL)-2 in antiviral drug-experienced human immunodeficiency virus-infected persons with detectable virus load: A controlled study of 3 IL-2 regimens with antiviral drug therapy
Authors: Tambussi, G Ghezzi, S Nozza, S Vallanti, G Magenta, L Guffanti, M Brambilla, A Vicenzi, E Carrera, P Racca, S Soldini, L Gianotti, N Murone, M Veglia, F Poli, G Lazzarin, A
Citation: G. Tambussi et al., Efficacy of low-dose intermittent subcutaneous interleukin (IL)-2 in antiviral drug-experienced human immunodeficiency virus-infected persons with detectable virus load: A controlled study of 3 IL-2 regimens with antiviral drug therapy, J INFEC DIS, 183(10), 2001, pp. 1476-1484
SMART - study on mutations and antiretroviral therapy: preliminary results
Authors: Gianotti, N Moretti, F Tambussi, G Nozza, S Ciuffreda, D Lazzarin, A Racca, S Boeri, E Crucianelli, R Ferrari, M Moroni, M Angarano, G Sinicco, A
Citation: N. Gianotti et al., SMART - study on mutations and antiretroviral therapy: preliminary results, SEVENTH EUROPEAN CONFERENCE ON CLINICAL ASPECTS AND TREATMENT OF HIV-INFECTION, 1999, pp. 87-91
Risultati: 1-3 |